This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Mantle Cell Lymphoma
and you are
over 18
years old
Phase
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The purpose of this study is to evaluate the efficacy and safety of ibrutinib in patients with mantle cell lymphoma who received at least 1 prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy.

Provided treatments

  • Drug: Ibrutinib
Tris trial is registered with FDA with number: NCT01599949. The sponsor of the trial is Janssen Research & Development, LLC and it is looking for 120 volunteers for the current phase.
Official trial title:
A Phase 2, Multicenter, Single-Arm, Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy